User login
The deadline has been extended to October 21 to submit letters of intent and abstracts for National Organization for Rare Disorders (NORD) research grants for studies related to the following rare diseases:
- Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV)
- Appendix cancer and pseudomyxoma peritonei (PMP)
- Autoimmune polyglandular syndrome type 1 (APS Type 1)
- Homocystinuria due to cystathionine beta-synthase deficiency
- Malonic aciduria
- Stiff person syndrome
The NORD Research Grant Program encourages meritorious scientific and clinical research toward new diagnostics, treatments, and/or cures for rare diseases. NORD’s program provides seed grants to clinicians and academic scientists for translational or clinical studies. Data generated in these studies may then be used by researchers to obtain additional funding from government or industry sponsors. Two of NORD’s previous research grants have resulted in FDA-approved orphan products to treat rare diseases. Submissions should be sent to [email protected]. Click here to view each Request for Proposal in full.
The deadline has been extended to October 21 to submit letters of intent and abstracts for National Organization for Rare Disorders (NORD) research grants for studies related to the following rare diseases:
- Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV)
- Appendix cancer and pseudomyxoma peritonei (PMP)
- Autoimmune polyglandular syndrome type 1 (APS Type 1)
- Homocystinuria due to cystathionine beta-synthase deficiency
- Malonic aciduria
- Stiff person syndrome
The NORD Research Grant Program encourages meritorious scientific and clinical research toward new diagnostics, treatments, and/or cures for rare diseases. NORD’s program provides seed grants to clinicians and academic scientists for translational or clinical studies. Data generated in these studies may then be used by researchers to obtain additional funding from government or industry sponsors. Two of NORD’s previous research grants have resulted in FDA-approved orphan products to treat rare diseases. Submissions should be sent to [email protected]. Click here to view each Request for Proposal in full.
The deadline has been extended to October 21 to submit letters of intent and abstracts for National Organization for Rare Disorders (NORD) research grants for studies related to the following rare diseases:
- Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV)
- Appendix cancer and pseudomyxoma peritonei (PMP)
- Autoimmune polyglandular syndrome type 1 (APS Type 1)
- Homocystinuria due to cystathionine beta-synthase deficiency
- Malonic aciduria
- Stiff person syndrome
The NORD Research Grant Program encourages meritorious scientific and clinical research toward new diagnostics, treatments, and/or cures for rare diseases. NORD’s program provides seed grants to clinicians and academic scientists for translational or clinical studies. Data generated in these studies may then be used by researchers to obtain additional funding from government or industry sponsors. Two of NORD’s previous research grants have resulted in FDA-approved orphan products to treat rare diseases. Submissions should be sent to [email protected]. Click here to view each Request for Proposal in full.